Employees
484
Industry
Pharmaceutical Preparation Manufacturing
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Loading...
Open
19.00
Mkt cap
795M
Volume
3.9M
High
19.01
P/E Ratio
-17.43
52-wk high
21.86
Low
18.98
Div yield
N/A
52-wk low
8.82
Portfolio Pulse from
November 12, 2024 | 1:30 pm
Portfolio Pulse from Vandana Singh
February 13, 2024 | 7:05 pm
Portfolio Pulse from Benzinga Newsdesk
November 10, 2023 | 1:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 26, 2023 | 1:09 pm
Portfolio Pulse from Lisa Levin
October 26, 2023 | 12:49 pm
Portfolio Pulse from Benzinga Newsdesk
October 13, 2023 | 7:57 pm
Portfolio Pulse from Benzinga Insights
October 02, 2023 | 5:35 pm
Portfolio Pulse from Benzinga Insights
September 28, 2023 | 5:35 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2023 | 4:18 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2023 | 3:25 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.